electroCore, Inc.
5.04+0.13 (+2.65%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · ECOR · USD
Key Stats
Market Cap
40.30MP/E (TTM)
-Basic EPS (TTM)
-1.60Dividend Yield
0%Recent Filings
8-K
Settles fees via stock issuance
electroCore settled outstanding legal fee obligations by issuing 360,737 shares of common stock at $5.145 per share to institutional and accredited investors on September 30, 2025, closing the deal October 2 without receiving cash proceeds. The unregistered shares rely on Section 4(a)(2) and Regulation D exemptions, with the company committing to file a resale registration statement effective within 90 days. This equity swap clears debts efficiently. Yet investors face resale delays until registration.
8-K
Board adds AI health expert
electroCore bolstered its board on September 2, 2025, appointing Elena Bonfiglioli, Microsoft's Global Business Leader for Healthcare and Pharma Life Sciences, as a Class II director to an expanded eight-member panel. The board also named Thomas J. Errico, M.D., as chairman, succeeding the retired F. Peter Cuneo, whose departure stemmed from no disagreements. This move aims to enhance governance amid AI-driven health innovations. Bonfiglioli brings two decades of expertise.
10-Q
Q2 FY2025 results
electroCore's Q2 FY2025 results showed revenue climbing 20% y/y to $7.4M, driven by stronger VA sales of gammaCore and emerging Truvaga wellness uptake, while gross margins edged up to 87% from better product mix. Yet operating expenses jumped 26% y/y to $9.9M on sales investments and NURO acquisition costs, yielding a $3.5M operating loss—wider than last year's $2.6M but with net loss expanding 38% y/y to $3.7M due to other expenses like professional fees. YTD revenue rose 22% y/y to $14.1M, with operating loss at $7.3M versus $6.4M prior; diluted EPS fell to $(0.44) from $(0.38), reconciling to 8.3M weighted shares. Cash dipped to $3.4M plus $3.8M marketable securities, but post-quarter $7.5M debt draw and $100M shelf filing bolster liquidity amid $12M total debt. Closed NURO acquisition in May 2025 for undisclosed terms, recognizing Quell Fibromyalgia synergies. Revenue concentration in VA remains a key risk.
8-K
Q2 sales hit record $7.4M
electroCore reported Q2 2025 net sales of $7.4 million, up 20% from $6.1 million in Q2 2024, fueled by 13% growth in VA gammaCore sales and 74% surge in Truvaga. Yet cash reserves dipped to $7.4 million amid $9.9 million operating expenses. The company completed its NeuroMetrix acquisition ahead of schedule. Full-year revenue guidance holds at $30 million, with net cash usage of $3.9–$4.4 million expected.
8-K
Q1 sales up 23%, acquisition closed
electroCore reported Q1 2025 net sales of $6.7 million, up 23% from $5.4 million in Q1 2024, driven by 22% growth in VA gammaCore sales to $4.7 million and 187% surge in Truvaga to $1.1 million, while TAC-STIM dropped 70%. Gross margins held steady at 85%, but operating expenses rose to $9.5 million from higher selling costs and $665,000 in non-recurring items tied to the NeuroMetrix acquisition, which closed in the quarter and added $170,000 in Quell sales. GAAP net loss widened slightly to $3.9 million, yet Adjusted EBITDA improved to a $3.1 million loss. For full-year 2025, the company guides $30.0 million in revenue, with NeuroMetrix contributing meaningfully by year-end. Cash burn remains a pressure point.
BWAY
Brainsway Ltd.
16.80+0.22
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.95+0.00
ELMD
Electromed, Inc.
24.01-0.43
EMED
Electromedical Technologies, In
0.00+0.00
EW
Edwards Lifesciences Corporatio
82.69+0.50
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NPCE
Neuropace, Inc.
10.13-0.49
NXL
Nexalin Technology, Inc.
1.55+0.07
STME
Stimcell Energetics, Inc.
0.44+0.03
VYCO
Vycor Medical, Inc.
0.15+0.00